Beta Amyloid PET/CT in Various Amyloid-Related Diseases

What this Trial Is About

Researchers are evaluating the usefulness of a diagnostic imaging test called 18F-92/AV45, 11C-PIB positron emission tomography/computed tomography (PET/CT) in patients with various Tau-related diseases, including primary and metastatic lesions. This study aims to better understand how well this PET/CT scan can detect amyloid-related disease lesions, which are linked to neurodegenerative conditions. The trial is observational and includes adult patients with suspected or diagnosed malignant tumors related to amyloid diseases. Participants will receive a single intravenous injection of the 18F-92/AV45, 11C-PIB tracer. After the injection, they will undergo a PET/CT or MRI scan within a specified time frame to assess the presence of lesions. The uptake of the tracer in lesions will be measured using a standardized uptake value (SUVmax), which helps quantify how much tracer is absorbed by the lesions. During the study, researchers will analyze the imaging results to determine the test's sensitivity, specificity, positive and negative predictive values, and overall accuracy in detecting lesions. Participants will be monitored for about 30 days, during which the standardized uptake value and diagnostic effectiveness will be the primary outcomes measured. The study includes adults aged 18 to 80 years and allows healthy volunteers to participate. Consent and assent are required according to ethical guidelines.

Beta Amyloid PET/CT in Various Aβ-Related Disease